{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T21:59:33Z","timestamp":1764539973877},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2003,10,9]],"date-time":"2003-10-09T00:00:00Z","timestamp":1065657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2003,11]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Chronic myeloproliferative disorders (MPD) are characterized by progressive remodelling of bone marrow stroma as evidenced by increased deposition of extracellular matrix proteins, neoangiogenesis and displacement of normal haematopoietic cells by fibrotic tissue. The family of metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs) serve to facilitate and inhibit matrix degradation processes, respectively. In an attempt to investigate potential markers for bone marrow remodelling processes, we investigated plasma levels of total\u2010, free\u2010 and complexed TIMP\u20101, TIMP\u20102, MMP\u20102 and MMP\u20109 in a patient cohort comprising 17 with myelofibrosis (MF), 17 with polycythaemia vera (PV), 15 with essential thrombocythaemia (ET), 1 with a transitional MPD and 30 controls. Compared with controls, total\u2010 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001) (median: 132.6\u2003<jats:italic>\u03bc<\/jats:italic>g\/L vs. 80.8\u2003<jats:italic>\u03bc<\/jats:italic>g\/L), free\u2010 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001) (median: 126.4\u2003<jats:italic>\u03bc<\/jats:italic>g\/L vs. 65.8\u2003<jats:italic>\u03bc<\/jats:italic>g\/L) and complexed TIMP\u20101 (<jats:italic>P<\/jats:italic>\u2003=\u20030.0009) (median: 17.7\u2003<jats:italic>\u03bc<\/jats:italic>g\/L vs. 10.7\u2003<jats:italic>\u03bc<\/jats:italic>g\/L) concentration was significantly higher in the patients. TIMP\u20101 was significantly correlated with plasma soluble urokinase plasminogen activator receptor (<jats:italic>P<\/jats:italic>\u2003=\u20030.003) and urokinase plasminogen activator (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001), respectively, suggesting a common cellular origin. No statistical significant difference between TIMP\u20102 and MMP\u20102 levels was observed between patients and controls. Furthermore, a significant correlation between free TIMP\u20101 and TIMP\u20102 levels was detected (<jats:italic>r<\/jats:italic>\u2003=\u20030.56; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). Median MMP\u20109 concentration was significantly higher among PV patients compared with controls (<jats:italic>P<\/jats:italic>\u2003=\u20030.0015), and 41% of patients with PV (7\/17) had MMP\u20109 values that were above the mean\u2003+\u20032SD of plasma MMP\u20109 levels found in controls. The ratio of total TIMP\u20101\/MMP\u20109 was significantly higher in patients with MF compared with controls (<jats:italic>P<\/jats:italic>\u2003=\u20030.0004). These findings suggest that a disturbed TIMP\u20101\/MMP ratio may reflect an imbalance of the extracellular homeostasis towards an increased matrix deposition promoting fibrosis.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2003.00096.x","type":"journal-article","created":{"date-parts":[[2003,10,16]],"date-time":"2003-10-16T01:38:59Z","timestamp":1066268339000},"page":"377-384","source":"Crossref","is-referenced-by-count":15,"title":["Elevated plasma levels of TIMP\u20101 correlate with plasma suPAR\/uPA in patients with chronic myeloproliferative disorders"],"prefix":"10.1111","volume":"71","author":[{"given":"Morten Krogh","family":"Jensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads Nikolaj","family":"Holten\u2010Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikke","family":"Riisbro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"de Nully Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maj Britt","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Heickendorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Br\u00fcnner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,9]]},"reference":[{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530160804"},{"key":"e_1_2_14_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(94)90071-X"},{"key":"e_1_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00870307"},{"key":"e_1_2_14_5_2","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood.V96.10.3374","article-title":"Evaluation and clinical correlations of bone marrow angiogensis in myelofibrosis with myeloid metaplasia","volume":"96","author":"Mesa RA","year":"2000","journal-title":"Blood"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050595"},{"key":"e_1_2_14_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00063-1"},{"key":"e_1_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02030.x"},{"key":"e_1_2_14_9_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4049\/jimmunol.160.2.691","article-title":"Adenovector\u2010mediated expression of human thrombopoietin cDNA in immune\u2010compromised mice: insights into the pathophysiology of osteomyelofibrosis","volume":"160","author":"Frey BM","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_14_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1342"},{"key":"e_1_2_14_11_2","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.4049\/jimmunol.153.6.2819","article-title":"Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines","volume":"153","author":"Rameshwar P","year":"1994","journal-title":"J Immunol"},{"key":"e_1_2_14_12_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00359.x"},{"key":"e_1_2_14_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2000.00004.x"},{"key":"e_1_2_14_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(99)00022-8"},{"key":"e_1_2_14_15_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.13.8.781"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1139\/y99-055"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.31.21491"},{"key":"e_1_2_14_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)36561-4"},{"key":"e_1_2_14_19_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/46.2.183","article-title":"Expression of matrix metalloproteinase\u20102 and \u20109 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C","volume":"46","author":"Lichtinghagen R","year":"2000","journal-title":"Clin Chem"},{"key":"e_1_2_14_20_2","first-page":"821","article-title":"Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin\u2010induced pulmonary fibrosis","volume":"152","author":"Swiderski RE","year":"1998","journal-title":"Am J Pathol"},{"key":"e_1_2_14_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240129"},{"key":"e_1_2_14_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb00045.x"},{"key":"e_1_2_14_23_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614906"},{"key":"e_1_2_14_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/386616a0"},{"key":"e_1_2_14_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.3064.h8003064_3064_3069"},{"key":"e_1_2_14_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.13.4152"},{"key":"e_1_2_14_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3293146.x"},{"key":"e_1_2_14_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(92)80386-U"},{"key":"e_1_2_14_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.12.4506.bloodjournal86124506"},{"key":"e_1_2_14_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03160.x"},{"key":"e_1_2_14_31_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.01732.x"},{"key":"e_1_2_14_32_2","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols","volume":"23","author":"Berk PD","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_14_33_2","first-page":"177","article-title":"Essential thrombocythemia: an interim report from the polycythemia vera study group","volume":"23","author":"Murphy S","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_14_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690384"},{"key":"e_1_2_14_35_2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/clinchem\/48.8.1305","article-title":"Measurement of non\u2010complexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay","volume":"48","author":"Holten\u2010Andersen MN","year":"2002","journal-title":"Clin Chem"},{"key":"e_1_2_14_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(93)90024-X"},{"key":"e_1_2_14_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.45.6.461"},{"key":"e_1_2_14_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64511-7"},{"key":"e_1_2_14_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03874.x"},{"key":"e_1_2_14_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830330105"},{"key":"e_1_2_14_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(199601)166:1<84::AID-JCP10>3.0.CO;2-P"},{"key":"e_1_2_14_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1987.tb02449.x"},{"key":"e_1_2_14_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000315)85:6<801::AID-IJC11>3.0.CO;2-C"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2003.00096.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2003.00096.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2003.00096.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T07:06:38Z","timestamp":1697180798000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2003.00096.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["10.1034\/j.1600-0609.2003.00096.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2003.00096.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,9]]}}}